Brian G.M. Durie
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments 242
- Acute Myeloid Leukemia Research 16
- Oncology top 0.1%
- Cancer Treatment and Pharmacology 65
- Peptidase Inhibition and Analysis 40
- Bone health and treatments 18
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 17
- Molecular Biology top 0.5%
- Protein Degradation and Inhibitors 78
- Amyloidosis: Diagnosis, Treatment, Outcomes 20
- Co-authors
- Sydney E. SalmonBart BarlogieDiane H. RussellDavid S. AlbertsJesús F. San MiguelPieter SonneveldThomas E. MoonB Soehnlen
- Cited by
- HematologyOncologyGenetics
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Brian G.M. Durie
275 papers receiving 14.9k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Hematology 11.6k
- Oncology 7.9k
- Genetics 1.9k
- Molecular Biology 8.7k
- Pathology and Forensic Medicine 959
Countries citing papers authored by Brian G.M. Durie
This map shows the geographic impact of Brian G.M. Durie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian G.M. Durie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian G.M. Durie more than expected).
Fields of papers citing papers by Brian G.M. Durie
This network shows the impact of papers produced by Brian G.M. Durie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian G.M. Durie. The network helps show where Brian G.M. Durie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Brian G.M. Durie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 11 | |
| 5 | 2023 | 0 | |
| 6 | 2022 | 6 | |
| 7 | 2021 | 13 | |
| 8 | 2021 | 92 | |
| 9 | 2021 | 10 | |
| 10 | 2018 | 29 | |
| 11 | 2017 | 2 | |
| 12 | 2016 | 48 | |
| 13 | 2014 | 5 | |
| 14 | IMWG consensus on risk stratification in multiple myelomabreakdown → | 2013 | 413 |
| 15 | Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) | 2011 | 4 |
| 16 | 2010 | 103 | |
| 17 | 2010 | 173 | |
| 18 | 2009 | 324 | |
| 19 | 2005 | 23 | |
| 20 | Polyamines as markers of response and disease activity in cancer chemotherapy. | 1977 | 170 |
About Brian G.M. Durie
Brian G.M. Durie is a scholar working on Hematology, Oncology and Genetics, having authored 289 papers that have together received 15.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (242 papers), Protein Degradation and Inhibitors (78 papers), Cancer Treatment and Pharmacology (65 papers), Peptidase Inhibition and Analysis (40 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (20 papers), Bone health and treatments (18 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Acute Myeloid Leukemia Research (16 papers). The work is most often cited by research in Hematology (11.6k citations), Oncology (7.9k citations) and Genetics (1.9k citations). Brian G.M. Durie has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Sydney E. Salmon, Bart Barlogie, Diane H. Russell, David S. Alberts, Jesús F. San Miguel, Pieter Sonneveld, Thomas E. Moon, B Soehnlen, Kazuyuki Shimizu and Robert A. Kyle. Their work appears in journals such as Science, New England Journal of Medicine and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.